FDA may ease peptide restrictions
- The Food and Drug Administration said it will hold a July 23-24, 2026 advisory committee meeting on seven peptides, a step that could reopen compounding access to substances restricted since 2023. - The July agenda includes BPC-157, TB-500, KPV, MOTs-C, Semax, Epitalon and emideltide, with FDA reviewing uses from wound healing and ulcerative colitis to obesity and osteoporosis. - The review follows Robert F. Kennedy Jr.’s push to loosen peptide rules after the Biden-era FDA put many on a list for “significant safety concerns.” (fda.gov)
Peptides are short chains of amino acids, the building blocks that also make up proteins. The Food and Drug Administration is now weighing whether some widely marketed peptide compounds should be allowed back into pharmacy compounding. (fda.gov) (biopharmadive.com) The agency scheduled a Pharmacy Compounding Advisory Committee meeting for July 23 and 24, 2026, at its White Oak campus in Silver Spring, Maryland, with online public access and a public comment docket open through July 22. (federalregister.gov) (fda.gov) On the July agenda are seven peptide groups: BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax and Epitalon. FDA says it is reviewing proposed uses that include ulcerative colitis, wound healing, inflammatory conditions, obesity, osteoporosis, sleep-related claims and cognitive claims. (fda.gov) Compounding is the practice of mixing or altering drugs for specific patients, such as removing an allergen or changing a dosage form. Under federal law, compounders can use bulk ingredients only in limited circumstances, including when a substance appears on FDA’s 503A or 503B bulks lists. (fda.gov) That legal detail is the center of this fight. If FDA eventually adds a peptide to the 503A bulks list, state-licensed pharmacies could compound it under that pathway even though the substance itself is not an FDA-approved drug. (fda.gov) (federalregister.gov) The backdrop is a Biden-era crackdown. In 2023, FDA placed 19 peptides into Category 2, a bucket for nominated substances that raise significant safety concerns and are not supposed to be used in compounding while the agency reviews them. (propublica.org) (biopharmadive.com) FDA’s current interim policy for section 503A compounding took effect in January 2025 and describes how the agency handles bulk substances while it continues building the permanent list. That framework is what the peptide review now runs through. (federalregister.gov) Health and Human Services Secretary Robert F. Kennedy Jr. has publicly pressed for broader peptide access and said on Joe Rogan’s podcast that he is a “big fan” of them. Associated Press reporting said the FDA meeting followed repeated Kennedy pledges to loosen peptide rules. (cbsnews.com) (biopharmadive.com) Former FDA officials and outside critics say the science has not caught up with the marketing. ProPublica reported that several former officials said the 2023 restrictions were backed by documented safety concerns and that little new clinical evidence has emerged since then. (propublica.org) The July meeting will not itself approve any peptide as a medicine. It will give FDA outside advice on whether these substances belong on a compounding list, a narrower decision that could still make them easier to obtain through clinics and pharmacies. (fda.gov 1) (fda.gov 2)
